Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers
Approximately 30–40% of male and 8–16% of female carriers of the Fragile X premutation will develop a neurodegenerative movement disorder characterized by intentional tremor, gait ataxia, autonomic dysfunction, cognitive decline, and Parkinsonism during their lifetime. At the molecular level, premut...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-08-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fgene.2018.00302/full |
id |
doaj-0908f581414d4d4285a756f52e88a12f |
---|---|
record_format |
Article |
spelling |
doaj-0908f581414d4d4285a756f52e88a12f2020-11-24T23:39:28ZengFrontiers Media S.A.Frontiers in Genetics1664-80212018-08-01910.3389/fgene.2018.00302354250Assessment of Molecular Measures in Non-FXTAS Male Premutation CarriersReem R. Al Olaby0Hiu-Tung Tang1Blythe Durbin-Johnson2Andrea Schneider3Andrea Schneider4David Hessl5David Hessl6Susan M. Rivera7Susan M. Rivera8Flora Tassone9Flora Tassone10Department of Biochemistry and Molecular Medicine, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesDepartment of Biochemistry and Molecular Medicine, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesDepartment of Biostatistics, University of California, Davis, Davis, CA, United StatesDepartment of Pediatrics, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesMIND Institute, UC Davis Medical Center, Sacramento, CA, United StatesMIND Institute, UC Davis Medical Center, Sacramento, CA, United StatesDepartment of Psychiatry and Behavioral Sciences, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesDepartment of Psychiatry and Behavioral Sciences, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesNeurocognitive Development Lab, Department of Psychology, UC Davis Center for Mind and Brain, University of California, Davis, Davis, CA, United StatesDepartment of Biochemistry and Molecular Medicine, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesDepartment of Pediatrics, UC Davis Medical Center, University of California, Davis, Davis, CA, United StatesApproximately 30–40% of male and 8–16% of female carriers of the Fragile X premutation will develop a neurodegenerative movement disorder characterized by intentional tremor, gait ataxia, autonomic dysfunction, cognitive decline, and Parkinsonism during their lifetime. At the molecular level, premutation carriers have increased expression levels of the FMR1 and the antisense FMR1 (ASFMR1) mRNAs. Both genes undergo alternative splicing giving rise to a number of different transcripts. Alteration in the alternative splicing process might be associated with FXTAS. In this study, we have investigated the correlation between objective measures of movement (balance and tremor using the CATSYS battery) and the expression of both the FMR1 and the ASFMR1 genes. In addition, we investigated whether their expression level and that of the ASFMR1 131 bp splice isoform could distinguish between premutation carriers with FXTAS and non-FXTAS premutation carriers. Confirming previous findings, the expression levels of transcripts at the FMR1 locus positively correlated with the CGG repeat number and significantly differentiated the premutation carriers from the control groups. Furthermore, premutation carriers with and without FXTAS, showed a significant difference in the expression level of the ASFMR1 131 bp splice isoform when compared to age and gender matched controls. However, there was no significant difference in the ASFMR1 131 bp splice isoform expression level when comparing premutation carriers with and without FXTAS. Finally, our results indicate significant group differences in CATSYS dominant hand reaction time and postural sway with eyes closed in premutation carriers without FXTAS compared to controls. In addition, a significant inverse association between the tremor intensity and the expression level of ASFMR1 131 bp splice isoform in premutation carriers compared to controls, was observed, suggesting a potential role in the pathogenesis of FXTAS.https://www.frontiersin.org/article/10.3389/fgene.2018.00302/fullFMR1ASFMR1transcriptionpremutationFXTASCATSYS |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Reem R. Al Olaby Hiu-Tung Tang Blythe Durbin-Johnson Andrea Schneider Andrea Schneider David Hessl David Hessl Susan M. Rivera Susan M. Rivera Flora Tassone Flora Tassone |
spellingShingle |
Reem R. Al Olaby Hiu-Tung Tang Blythe Durbin-Johnson Andrea Schneider Andrea Schneider David Hessl David Hessl Susan M. Rivera Susan M. Rivera Flora Tassone Flora Tassone Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers Frontiers in Genetics FMR1 ASFMR1 transcription premutation FXTAS CATSYS |
author_facet |
Reem R. Al Olaby Hiu-Tung Tang Blythe Durbin-Johnson Andrea Schneider Andrea Schneider David Hessl David Hessl Susan M. Rivera Susan M. Rivera Flora Tassone Flora Tassone |
author_sort |
Reem R. Al Olaby |
title |
Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers |
title_short |
Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers |
title_full |
Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers |
title_fullStr |
Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers |
title_full_unstemmed |
Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers |
title_sort |
assessment of molecular measures in non-fxtas male premutation carriers |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Genetics |
issn |
1664-8021 |
publishDate |
2018-08-01 |
description |
Approximately 30–40% of male and 8–16% of female carriers of the Fragile X premutation will develop a neurodegenerative movement disorder characterized by intentional tremor, gait ataxia, autonomic dysfunction, cognitive decline, and Parkinsonism during their lifetime. At the molecular level, premutation carriers have increased expression levels of the FMR1 and the antisense FMR1 (ASFMR1) mRNAs. Both genes undergo alternative splicing giving rise to a number of different transcripts. Alteration in the alternative splicing process might be associated with FXTAS. In this study, we have investigated the correlation between objective measures of movement (balance and tremor using the CATSYS battery) and the expression of both the FMR1 and the ASFMR1 genes. In addition, we investigated whether their expression level and that of the ASFMR1 131 bp splice isoform could distinguish between premutation carriers with FXTAS and non-FXTAS premutation carriers. Confirming previous findings, the expression levels of transcripts at the FMR1 locus positively correlated with the CGG repeat number and significantly differentiated the premutation carriers from the control groups. Furthermore, premutation carriers with and without FXTAS, showed a significant difference in the expression level of the ASFMR1 131 bp splice isoform when compared to age and gender matched controls. However, there was no significant difference in the ASFMR1 131 bp splice isoform expression level when comparing premutation carriers with and without FXTAS. Finally, our results indicate significant group differences in CATSYS dominant hand reaction time and postural sway with eyes closed in premutation carriers without FXTAS compared to controls. In addition, a significant inverse association between the tremor intensity and the expression level of ASFMR1 131 bp splice isoform in premutation carriers compared to controls, was observed, suggesting a potential role in the pathogenesis of FXTAS. |
topic |
FMR1 ASFMR1 transcription premutation FXTAS CATSYS |
url |
https://www.frontiersin.org/article/10.3389/fgene.2018.00302/full |
work_keys_str_mv |
AT reemralolaby assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers AT hiutungtang assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers AT blythedurbinjohnson assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers AT andreaschneider assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers AT andreaschneider assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers AT davidhessl assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers AT davidhessl assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers AT susanmrivera assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers AT susanmrivera assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers AT floratassone assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers AT floratassone assessmentofmolecularmeasuresinnonfxtasmalepremutationcarriers |
_version_ |
1725513438995677184 |